Vice President of Product Innovation GenomOncology, Ohio, United States
This collaborative presentation showcases the groundbreaking partnership between Belay Diagnostics and GenomOncology, featuring Summit™—the only purpose-built liquid biopsy test analyzing tumor-derived DNA in cerebrospinal fluid with integrated genomic reporting.
Honey V. Reddi, PhD, FACMG (Belay) and Matthew Stachowiak, PhD (GenomOncology) will present real-world patient cases demonstrating how CSF liquid biopsies revolutionize CNS tumor management. Attendees will discover Summit's clinical validity across metastatic brain cancers, gliomas, GBMs, medulloblastomas, and astrocytomas, learning how this technology provides a minimally invasive alternative to conventional cytology, imaging, and brain biopsies. The session covers tumor detection, classification, disease monitoring, and treatment selection, with interactive clinical application discussions and exploration of future diagnostic directions in neuro-oncology and genomic reporting.
